Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.42K$15.42Kderivedno prior Q4 2014 on file Net Income-$6.32M-$6.32MderivedN/M vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$2,140— Operating Incomederived-$6,308,945— Operating Cash Flowderived-$918,111N/M Free Cash Flowderived-$918,090N/M Margins · derivedGross margin-13.9%
Operating margin-40922.0%
Net margin-41003.1%
ended Dec 31, 2015 · filed Apr 14, 2016 · 105 d after period end